Search

Background: Real-world data on long-term outcomes of vedolizumab (VDZ) are scarce., Objective: To assess long-term outcomes (up to 3 years) of VDZ in treating inflammatory bowel disease (IBD)., Design: A nationwide, prospective multicentre extension of a Swedish observational study on VDZ assessing Effectiveness And Healthcare resource utilization in patients with IBD (SVEAH)., Methods: After re-consent, data of patients with Crohn's disease (CD) ( n  = 68) and ulcerative colitis (UC) ( n  = 46) treated with VDZ were prospectively recorded using an electronic case report form integrated with the Swedish IBD Register (SWIBREG). The primary outcome was clinical remission (defined as Harvey-Bradshaw Index ⩽4 in CD and partial Mayo score ⩽2 in UC) at 104 and 156 weeks in patients with a response and/or remission 12 weeks after starting VDZ. Secondary outcomes included health-related quality of life (HRQoL) and biochemical outcomes., Results: VDZ continuation rates were high at weeks 104 and 156, 88% and 84%, respectively, for CD and 87% and 78%, respectively, for UC. Of the 53 CD patients with a response/remission at 12 weeks, 40 (75%) patients were in remission at 104 weeks and 42 (79%) patients at 156 weeks. For UC, these numbers were 25/31 (81%) and 22/31 (71%), respectively. Improvements were seen in the Short Health Scale ( p  < 0.01 for each dimension; CD, n  = 51; UC, n  = 33) and the EuroQol 5-Dimensions, 5-levels index value ( p  < 0.01; CD, n  = 39; UC, n  = 30). Median plasma-C-reactive protein concentrations (mg/L) decreased from 5 at baseline to 4 in CD ( p  = 0.01, n  = 53) and from 5 to 4 in UC ( p  = 0.03, n  = 34) at 156 weeks. Correspondingly, median faecal-calprotectin (µg/g) decreased from 641 to 114 in CD patients ( p  < 0.01, n  = 26) and from 387 to 37 in UC patients ( p  = 0.02, n  = 17)., Conclusion: VDZ demonstrated high continuation rates and was associated with improvements in clinical outcomes, HRQoL measures and inflammatory markers at 2 and 3 years after treatment initiation in this prospective national SVEAH extension study., Registration: ENCePP registration number: EUPAS22735., Competing Interests: IV has served as a speaker for Takeda. CE has received grant support/lecture fee/advisory board from Takeda, Janssen Cilag, Pfizer and AbbVie. SK has served as a speaker for Takeda. BL: None. PK: None. OG has received consultant fees from Ferring, Takeda, Janssen, AbbVie, Pfizer and Tillotts Pharma. CS: None. SA has received research grants from Karolinska Institutet, Thuréus foundation and Janssen, as well as served as a consultant for Takeda, Janssen. EH has served as a speaker, consultant or advisory board member for AbbVie, Gilead, Janssen, Pfizer and Takeda. JM has served as a speaker, consultant or advisory board member for AbbVie, Bayer, BMS, Hospira, Janssen, MSD, Pfizer, Sandoz, Takeda and UCB and has received grant support from AbbVie, Calpro AS, Fresenius Kabi, Pfizer, SVAR Life Science and Takeda. CM serves as an employee at Takeda. JD: None. HS has served as a speaker or advisory board member for AbbVie, Ferring, Janssen, Pfizer, Takeda, Gilead and Tillotts Pharma. MS: None. DB has received personal fees from Ferring, Takeda, Janssen and BMS outside the submitted work. HH has served as a speaker, consultant or advisory board member for AbbVie, Janssen, Pfizer, Takeda, Tillotts Pharma, Vifor Pharma and received grant support from Ferring and Tillotts Pharma. JH has served as a speaker, consultant and/or advisory board member for AbbVie, Aqilion, BMS, Celgene, Celltrion, Ferring, Galapagos, Gilead, Hospira, Janssen, MEDA, Medivir, MSD, Novartis, Pfizer, Prometheus Laboratories Inc, Sandoz, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma and Vifor Pharma. JH has also received grant support from Janssen, MSD and Takeda., (© The Author(s), 2023.)

Background and Aim: Detection of advanced fibrosis (F3-F4) in nonalcoholic fatty liver disease (NAFLD) is important for ascertaining prognosis. Serum markers have been proposed as alternatives to biopsy. We attempted to develop a novel algorithm for detection of advanced fibrosis based on a more efficient combination of serological markers and to compare this with established algorithms., Methods: We included 158 patients with biopsy-proven NAFLD. Of these, 38 had advanced fibrosis. The following fibrosis algorithms were calculated: NAFLD fibrosis score, BARD, NIKEI, NASH-CRN regression score, APRI, FIB-4, King´s score, GUCI, Lok index, Forns score, and ELF. Study population was randomly divided in a training and a validation group. A multiple logistic regression analysis using bootstrapping methods was applied to the training group. Among many variables analyzed age, fasting glucose, hyaluronic acid and AST were included, and a model (LINKI-1) for predicting advanced fibrosis was created. Moreover, these variables were combined with platelet count in a mathematical way exaggerating the opposing effects, and alternative models (LINKI-2) were also created. Models were compared using area under the receiver operator characteristic curves (AUROC)., Results: Of established algorithms FIB-4 and King´s score had the best diagnostic accuracy with AUROCs 0.84 and 0.83, respectively. Higher accuracy was achieved with the novel LINKI algorithms. AUROCs in the total cohort for LINKI-1 was 0.91 and for LINKI-2 models 0.89., Conclusion: The LINKI algorithms for detection of advanced fibrosis in NAFLD showed better accuracy than established algorithms and should be validated in further studies including larger cohorts., Competing Interests: The authors have declared that no competing interests exist.